Board of Directors

Alexander Beard

Non-Executive Director, Chairman

Mr Beard has extensive experience with investee businesses, both in providing advice and in direct management roles, especially bringing management expertise to early-stage businesses. He has implemented management information systems, financial reporting systems, and internal operating and control procedures. He has also assisted businesses in value engineering product ranges and introducing market-oriented product lines.

Mr Beard has implemented significant company restructuring and recruited new management teams for growth businesses. His negotiation experience includes successes in private placement and in contractual arrangements involving banking facilities, distribution arrangements and processing agreements.

Greg Lan

Non-Executive Director

Mr Lan joined the Probiotec board in February 2017. Mr Lan was the founding Managing Director of Sydney-based pharmaceutical company Aspen Pharmacare Australia, a subsidiary of South African listed Aspen Pharmacare Holdings. During Mr Lan’s tenure, Aspen Australia experienced exponential growth, particularly after the acquisition of Sigma’s branded and generics portfolio in 2011 (as well as its manufacturing facilities), and is today one of Australia’s largest pharmaceutical companies, with a diverse portfolio of over 260 products covering prescription and OTC. When Mr Lan retired after 15 years with the company, Aspen’s Asia Pacific operations (including Australia) had annualised sales in excess of $1 billion.

Prior to joining Aspen, Mr Lan has had extensive experience working in the pharmaceutical industry internationally, including senior roles with Ciba-Geigy (now Novartis) in Switzerland and Saudi Arabia, as well as with Sanofi-Aventis in Australia. Mr Lan holds an MBA from the University of Michigan.

Jonathan Wenig

Non-Executive Director

Mr Wenig is currently a partner at Arnold Bloch Leibler, a leading Australian commercial law firm. Mr Wenig’s practice and expertise spans the breadth of commercial and corporate law, including mergers and acquisitions, corporate work, technology and financing. He is a trusted advisor to numerous active and innovative public companies – bringing his intellect and experience to bear not only in their corporate matters and acquisition activities, but across their legal affairs and strategic challenges and opportunities.
Mr Wenig is ranked as one of Australia’s leading Corporate and M&A lawyers in Chambers Asia Pacific and The Legal 500 Asia Pacific. He is also recognised by Best Lawyers® International in the area of corporate and M&A law and has been ranked by Doyle’s Guide in the categories of private equity and corporate law.

Wesley Stringer

Executive Director, Chief Executive Officer

Prior to joining Probiotec, Mr Stringer was employed by KPMG in Taxation and Finance. He has also worked internationally for Deutsche Bank and BNP Paribas Investment Bank in London.

Qualifications: B.Comm (Accounting, Finance), LLB (hons), CPA.